Avastin (bevacizumab, rhuMAb-VEGF)
Published: Oct 15, 2008 8:00 am
| Brand Name: | Avastin |
| Generic Name: | bevacizumab |
| Code Name: | rhuMAb-VEGF |
| Company: | Genentech Inc. |
| FDA Clinical Phase: | 1/2 |
Description:
Avastin is a monoclonal antibody used in the treatment of colorectal cancer that has spread. It is also being studied in the treatment of other types of cancer. Avastin binds to vascular endothelial growth factor (VEGF) and may stop the growth of new blood vessels needed for tumors to grow. It is a type of antiangiogenesis agent.
Clinical Trials:
For a list of clinical trials studying Avastin for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official website for Avastin: http://www.avastin.com/
Source: NCI Cancer Glossary, Avastin, http://www.cancer.gov/templates/db_alpha.aspx?searchTxt=Avastin (as of September 8, 2008)
Related Articles:
- Getting To Know: Tiragolumab
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
- Darzalex May Affect Different Uninvolved Immunoglobulins Differently
- Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2018)
- Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients
